{
  "created_at": "Fri Feb 19 6:32:38 +0000 2021",
  "id_str": "1362543707640258565",
  "full_text": "As puberty blockers are not licensed for gender medicine, drug firms have done no trials on their effect on gender-dysphoric children. The few studies that do exist are weak and worrying https://t.co/cRRgXk83nT",
  "display_text_range": [
    0,
    210
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/cRRgXk83nT",
        "expanded_url": "https://econ.st/3pt3EC9",
        "display_url": "econ.st/3pt3EC9",
        "indices": [
          187,
          210
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 37,
  "favorite_count": 78,
  "possibly_sensitive": false,
  "original_created_at": "Thu Feb 18 23:25:09 +0000 2021",
  "localize": [
    {
      "locale": "zh",
      "full_text": "由于青春期阻断剂没有获得性别药的许可，药企没有做过对性别障碍儿童效果的试验。现有的几项研究都很薄弱，令人担忧https://t.co/cRRgXk83nT。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "由於青春期阻斷劑沒有獲得性別藥的許可，藥企沒有做過對性別障礙兒童效果的試驗。現有的幾項研究都很薄弱，令人擔憂https://t.co/cRRgXk83nT。"
    }
  ]
}